目的:分析双操作通道全内镜下远外侧经椎间孔入路腰椎椎间融合术治疗腰椎滑脱症的临床疗效。方法:回顾性分析2023年6月~2023年12月我科接受双操作通道全内镜下远外侧经椎间孔入路腰椎椎间融合术治疗的单节段腰椎滑脱症患者的临床资料共2...目的:分析双操作通道全内镜下远外侧经椎间孔入路腰椎椎间融合术治疗腰椎滑脱症的临床疗效。方法:回顾性分析2023年6月~2023年12月我科接受双操作通道全内镜下远外侧经椎间孔入路腰椎椎间融合术治疗的单节段腰椎滑脱症患者的临床资料共20例;其中退变性腰椎滑脱15例,峡部裂型腰椎滑脱5例;女7例,男13例;年龄49~72(59.95±7.16)岁;病程为2~120(35.15±42.10)个月。记录手术时间、术中出血量、住院时间及手术并发症,术前、术后1个月及末次随访时应用腰椎Oswestry功能障碍指数(Oswestry disability index,ODI)、腰痛及腿痛的视觉模拟评分(visual analog scale,VAS)评价疗效。对随访期间腰椎CT影像按照Bridwell标准判断椎间融合情况。结果:所有患者顺利完成镜下融合手术;手术时间为175~235min(201.75±24.40min)。所有病例随访时间为12~16(14.15±1.14)个月。术后1个月及末次随访时ODI、腰痛及腿痛VAS评分均较术前明显改善(P<0.05)。术中、术后及末次随访时均无严重并发症发生。随访期间20例复查腰椎CT,其中19例(95.0%)达到骨性融合。结论:双操作通道全内镜下远外侧经椎间孔入路腰椎椎间融合术早期随访临床疗效令人满意,是治疗腰椎滑脱症的一种微创、安全、有效的术式选择。展开更多
生物制剂及口服小分子(oral small molecule,OSM)药物为儿科皮肤病,如特应性皮炎、银屑病、斑秃以及化脓性汗腺炎等的治疗提供了全新思路。虽然大部分生物制剂及OSM药物仅获批应用于成年患者,但随着其临床安全性评估的持续强化,以及在...生物制剂及口服小分子(oral small molecule,OSM)药物为儿科皮肤病,如特应性皮炎、银屑病、斑秃以及化脓性汗腺炎等的治疗提供了全新思路。虽然大部分生物制剂及OSM药物仅获批应用于成年患者,但随着其临床安全性评估的持续强化,以及在青少年及儿童中应用的逐步获批,生物制剂及OSM药物有望成为未来儿童皮肤病用药的新选择。该文全面梳理近年来美国食品药品监督管理局批准或具备用于治疗儿童特应性皮炎、银屑病、斑秃及化脓性汗腺炎潜力的生物制剂及OSM药物,以期为相关疾病的治疗提供参考。展开更多
In this paper,we introduce the concept of the L_(p,s)-Gaussian surface area measure of a convex body in n-dimensional Euclidean space R^(n) and formulate the corresponding L_(p,s)-Gaussian-Minkowski problem:Given a fi...In this paper,we introduce the concept of the L_(p,s)-Gaussian surface area measure of a convex body in n-dimensional Euclidean space R^(n) and formulate the corresponding L_(p,s)-Gaussian-Minkowski problem:Given a finite Borel measureμon S^(n-1),what are the necessary and sufficient conditions for the existence of a convex body whose L_(p,s)-Gaussian surface area measure equals measure μ?Furthermore,we present a solution to the L_(p,s)-Gaussian-Minkowski problem for the case of even measures.展开更多
Background:Atopic eczema is the most common type of skin disorder in both children and adults.It is characterized by erythema,pruritus,papules,xeransis,and lichenification.The KangminⅠdecoction,a Chinese herbal medic...Background:Atopic eczema is the most common type of skin disorder in both children and adults.It is characterized by erythema,pruritus,papules,xeransis,and lichenification.The KangminⅠdecoction,a Chinese herbal medicine prepared with several ingredients and used to treat eczema,was formulated according to traditional Chinese medicine theory.Objectives:To investigate the efficacy and safety of KangminⅠdecoction for treating atopic eczema compared to that of loratadine.Methods:90 patients were enrolled at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine and randomly divided into the KangminⅠdecoction treatment group(n=45)and loratadine control group(n=45).Clinical efficacy was evaluated using the Eczema Area and Severity Index(EASI),Dermatology Life Quality Index(DLQI),adverse events(AEs),and recurrence rates,which were compared between the groups.Results:Compared to the loratadine control group(51.16%,18.60%),the KangminⅠdecoction group(7.72%,4.55%)displayed a significantly reduced effective rate(x^(2)=8.324,P=0.040)and recurrence rate(x^(2)=4.225,P=0.040).The incidence of AEs was similar between the groups(P=0.502).Conclusions:These results support further development of KangminⅠdecoction for the treatment of eczema.The KangminⅠdecoction showed good efficacy with a low recurrence rate and tolerable AEs.The main limitations of this study include the small sample size and the short treatment and follow-up periods.Larger controlled studies are needed to more adequately evaluate both safety and efficacy.展开更多
文摘目的:分析双操作通道全内镜下远外侧经椎间孔入路腰椎椎间融合术治疗腰椎滑脱症的临床疗效。方法:回顾性分析2023年6月~2023年12月我科接受双操作通道全内镜下远外侧经椎间孔入路腰椎椎间融合术治疗的单节段腰椎滑脱症患者的临床资料共20例;其中退变性腰椎滑脱15例,峡部裂型腰椎滑脱5例;女7例,男13例;年龄49~72(59.95±7.16)岁;病程为2~120(35.15±42.10)个月。记录手术时间、术中出血量、住院时间及手术并发症,术前、术后1个月及末次随访时应用腰椎Oswestry功能障碍指数(Oswestry disability index,ODI)、腰痛及腿痛的视觉模拟评分(visual analog scale,VAS)评价疗效。对随访期间腰椎CT影像按照Bridwell标准判断椎间融合情况。结果:所有患者顺利完成镜下融合手术;手术时间为175~235min(201.75±24.40min)。所有病例随访时间为12~16(14.15±1.14)个月。术后1个月及末次随访时ODI、腰痛及腿痛VAS评分均较术前明显改善(P<0.05)。术中、术后及末次随访时均无严重并发症发生。随访期间20例复查腰椎CT,其中19例(95.0%)达到骨性融合。结论:双操作通道全内镜下远外侧经椎间孔入路腰椎椎间融合术早期随访临床疗效令人满意,是治疗腰椎滑脱症的一种微创、安全、有效的术式选择。
文摘生物制剂及口服小分子(oral small molecule,OSM)药物为儿科皮肤病,如特应性皮炎、银屑病、斑秃以及化脓性汗腺炎等的治疗提供了全新思路。虽然大部分生物制剂及OSM药物仅获批应用于成年患者,但随着其临床安全性评估的持续强化,以及在青少年及儿童中应用的逐步获批,生物制剂及OSM药物有望成为未来儿童皮肤病用药的新选择。该文全面梳理近年来美国食品药品监督管理局批准或具备用于治疗儿童特应性皮炎、银屑病、斑秃及化脓性汗腺炎潜力的生物制剂及OSM药物,以期为相关疾病的治疗提供参考。
基金Supported by the National Natural Science Foundation of China(11971080,12371137)。
文摘In this paper,we introduce the concept of the L_(p,s)-Gaussian surface area measure of a convex body in n-dimensional Euclidean space R^(n) and formulate the corresponding L_(p,s)-Gaussian-Minkowski problem:Given a finite Borel measureμon S^(n-1),what are the necessary and sufficient conditions for the existence of a convex body whose L_(p,s)-Gaussian surface area measure equals measure μ?Furthermore,we present a solution to the L_(p,s)-Gaussian-Minkowski problem for the case of even measures.
基金sponsored by the National Key Research and Development Program(No.2024YFC3500314)the National Natural Science Foundation of China(No.82405403)+3 种基金the Shanghai 2022‘Science and Technology Innovation Action Plan’Medical Innovation Research Special Project(No.22Y11922200)the Key Discipline Construction Project of Shanghai’s Three Year Action Plan for Strengthening the Construction of Public Health System(No.GWVI-11.1-24)the Clinical Research plan of Shanghai Shenkang HospitalDevelopment Center(No.SHDC22022302)the High-level Chinese Medicine Key Discipline Construction Project(Integrative Chinese and Western Medicine Clinic)of National Administration of TCM(No.zyyzdxk-2023065).
文摘Background:Atopic eczema is the most common type of skin disorder in both children and adults.It is characterized by erythema,pruritus,papules,xeransis,and lichenification.The KangminⅠdecoction,a Chinese herbal medicine prepared with several ingredients and used to treat eczema,was formulated according to traditional Chinese medicine theory.Objectives:To investigate the efficacy and safety of KangminⅠdecoction for treating atopic eczema compared to that of loratadine.Methods:90 patients were enrolled at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine and randomly divided into the KangminⅠdecoction treatment group(n=45)and loratadine control group(n=45).Clinical efficacy was evaluated using the Eczema Area and Severity Index(EASI),Dermatology Life Quality Index(DLQI),adverse events(AEs),and recurrence rates,which were compared between the groups.Results:Compared to the loratadine control group(51.16%,18.60%),the KangminⅠdecoction group(7.72%,4.55%)displayed a significantly reduced effective rate(x^(2)=8.324,P=0.040)and recurrence rate(x^(2)=4.225,P=0.040).The incidence of AEs was similar between the groups(P=0.502).Conclusions:These results support further development of KangminⅠdecoction for the treatment of eczema.The KangminⅠdecoction showed good efficacy with a low recurrence rate and tolerable AEs.The main limitations of this study include the small sample size and the short treatment and follow-up periods.Larger controlled studies are needed to more adequately evaluate both safety and efficacy.
